Prognostic significance of MGMT and IDH1 in patients with secondary glioblastoma

被引：0
|
作者：
Bie, L. [1 ]
Zhang, X. [1 ]
Li, M. [1 ]
机构：
[1] Jilin Univ, Hosp 1, Neurosurg, Changchun 130023, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MC13-0004
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] Validation of Prognostic Significance of IDH1 and MGMT in Patients with Glioblastoma: One Step Forward, and One Step Back?
    Combs, S.
    Abdollahi, A.
    Rieken, S.
    von Deimling, A.
    Wick, W.
    Debus, J.
    Hartmann, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S9 - S10
  • [2] IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme
    Kalkan, Rasime
    Atli, Emine Ikbal
    Ozdemir, Muhsin
    Ciftci, Evrim
    Aydin, Hasan Emre
    Artan, Sevilhan
    Arslantas, Ali
    GENE, 2015, 554 (01) : 81 - 86
  • [3] The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone
    Molenaar, Remco J.
    Verbaan, Dagmar
    Lamba, Simona
    Zanon, Carlo
    Jeuken, Judith W. M.
    Boots-Sprenger, Sandra H. E.
    Wesseling, Pieter
    Hulsebos, Theo J. M.
    Troost, Dirk
    van Tilborg, Angela A.
    Leenstra, Sieger
    Vandertop, W. Peter
    Bardelli, Alberto
    van Noorden, Cornelis J. F.
    Bleeker, Fonnet E.
    NEURO-ONCOLOGY, 2014, 16 (09) : 1263 - 1273
  • [4] MGMT promoter methylation and IDH1 mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme.
    Wozniak, A.
    Van Mieghem, E.
    Ardon, H.
    De Vleeschouwer, S.
    Menten, J.
    Sciot, R.
    Van Calenbergh, F.
    Van Gool, S.
    Debiec-Rychter, M.
    Clement, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813
    Fleming, J. L.
    Pugh, S.
    Bell, E. H.
    Chang, S. M.
    McElroy, J.
    Becker, A.
    Timmers, C. D.
    Shih, H. A.
    Ashby, L.
    Hunter, G. K.
    Bahary, J. P.
    Schultz, C. J.
    Kavanagh, B. D.
    Yung, W. A.
    Robins, I.
    Werner-Wasik, M.
    Chakravarti, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (05): : 1399 - 1399
  • [6] Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
    Mahmoud, Magda Sayed
    Khalifa, Mohamed K.
    Nageeb, Amira M.
    El-Arab, Lobna R. Ezz
    El-Mahdy, Manal
    Ramadan, Amal
    Hashim, Maha
    Bakr, Noha M.
    Swellam, Menha
    EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2024, 25 (01)
  • [7] Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
    Magda Sayed Mahmoud
    Mohamed K. Khalifa
    Amira M. Nageeb
    Lobna R. Ezz El-Arab
    Manal El-Mahdy
    Amal Ramadan
    Maha Hashim
    Noha M. Bakr
    Menha Swellam
    Egyptian Journal of Medical Human Genetics, 25
  • [8] Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
    Stephanie E Combs
    Stefan Rieken
    Wolfgang Wick
    Amir Abdollahi
    Andreas von Deimling
    Jürgen Debus
    Christian Hartmann
    Radiation Oncology, 6
  • [9] Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
    Combs, Stephanie E.
    Rieken, Stefan
    Wick, Wolfgang
    Abdollahi, Amir
    von Deimling, Andreas
    Debus, Juergen
    Hartmann, Christian
    RADIATION ONCOLOGY, 2011, 6
  • [10] THE PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF PARTIAL MGMT PROMOTER METHYLATION FOR IDH-WILDTYPE GLIOBLASTOMA PATIENTS
    Torre, Matthew
    Iorgulescu, Bryan
    NEURO-ONCOLOGY, 2022, 24 : 10 - 10
12345